Sanofi to research new types of antibiotics with Rib-X Pharmaceuticals

---

Sanofi has signed a research collaboration with Rib-X Pharmaceuticals to investigate new types of antibiotics

06 July 2011


"The French pharma company has taken an option to licence Rib-X’s novel classes of antibiotics in return for an upfront payment of $10 million and further milestones that could be worth more than $186 million per product developed.

The partners aim to produce treatments for multi-drug resistant bacteria, infections from which are responsible for at least 25,000 patient deaths in the European Union each year."

     .........

http://www.inpharm.com/news/161747/sanofi-rib-x-pharmaceuticals-antibiotics-research

--

http://en.sanofi.com/home.asp

--

http://www.rib-x.com

--------


Dateline -- San Diego, Calif.:  08 July 2011 -- 9:00 PM

Posted by:

David A. Palella
Founder
BIOSCIENCE VENTURES Inc.

San Diego, California
cell: 619-787-5767
email:  dpalella@gmail.com
http://www.linkedin.com/in/davidpalella

web site:  http://www.BSVpartners.com

blog: http://biobizdev.blogspot.com


& Group Founder:

Infectious Disease R&D and Business Network
http://www.linkedin.com/e/-ubgx8c-godydbie-43/vgh/3937807/

Japan Biotech / Biopharma Partnering Forum
http://www.linkedin.com/e/vgh/2857975/

Biotech / Pharma Business Development, Licensing & Dealmaking
http://www.linkedin.com/e/-ubgx8c-gp40f4dt-22/vgh/3964633/

Asia Business & Finance Roundup
http://www.linkedin.com/e/vgh/3132759/

Biofuels & Sustainable Chemicals Networking Group
http://www.linkedin.com/e/vgh/3891375/

X-tech Roundup(SM) - San Diego
http://www.linkedin.com/e/vgh/2836926


& Co-founder:

Stem Cells & Regenerative Medicine
http://www.linkedin.com/e/vgh/3921448

---------